A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

NCT05210868 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

184

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematoma

Interventions

DRUG: CM355

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.